drugset / Trial / NCT07272109

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

NCT07272109 ↗

Phase 3 Not yet recruiting 210 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of anti-diabetic treatment on improving the overall survival for metastatic pancreatic cancer patients complicated by diabetes receiving gemcitabine and nab-paclitaxel chemotherapy.

Timeline

Start
2026-01-01
Primary completion
2027-12-30
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Background Gemcitabine Small molecule 1000 mg/m2 —
Background Nab-paclitaxel Small molecule 120 mg/m2 —